Fig. 6

Effects of long-term peripheral myeloid cell engraftment on behavior and cognition. (a–d) Quantification of elevated plus maze performance at 1 month (a–b) and 6 months (c–d) post CSF1Ri treatment in control (WT CON), irradiated (GFP-BM CON), and monocyte-engrafted (GFP-BM REPOP) mice as assessed by time spent in open and closed arms (b, d). Total distance moved was also measured to control for locomotive changes (a, c). (e–j) Quantification of open field (e, h) and novel place recognition (g, j) performance at 1 month (e–g) and 6 months (h–j) as assessed by total distance moved (e, h) and percent preference index (f–g, i–j), respectively. Preference index is the ratio of the amount of time spent exploring any one of two objects (A or B) in the training phase or the novel-placed object (C) in the test phase over the total time spent exploring both objects, i.e. C/(B + C) × 100 in the test phase. Quantification of training also provided (f, i). (k–n) Quantification of rotarod performance at 1 months (k–l) and 6 months (m–n). (o–r) Quantification of contextual fear conditioning at 1 months (o–p) and 6 months (q–r) post CSF1Ri-induced monocyte engraftment as assessed by percentage of inactivity at testing (p, r). Quantification of training also provided (o, q). s–t Quantification of social interaction test performance at 6 months post CSF1Ri treatment as assessed by time spent in an empty zone or zone containing a stranger mouse (t). Total distance moved was also measured to control for locomotive changes (s). u–w Quantification of spontaneous alternation (Y-maze) performance at 6 months post CSF1Ri treatment as assessed by zone alternation frequency (w). Total distance moved and total number of arm entries was also measured to control for locomotive changes (u) and motivation/movement (v), respectively. *p < 0.05. ***p < 0.001